ArticleArchives of dermatology2008
Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling.
Article in Archives of dermatology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 66 citations in OpenAlex.
- Does imiquimod pretreatment optimize 308-nm excimer laser (UVB) therapy in psoriasis patients?Photodermatology, photoimmunology & photomedicine · 2017Trial
- Development of siRNAs targeting interferon beta as a novel therapeutic approach for adult and juvenile dermatomyositis.Frontiers in immunology · 2026Article
- Idiopathic inflammatory myopathies related lung disease in adults.The Lancet. Respiratory medicine · 2025Review
- Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure.JAAD case reports · 2024Article
- Type I Interferons in Systemic Autoimmune Rheumatic Diseases: Pathogenesis, Clinical Features and Treatment Options.Mediterranean journal of rheumatology · 2024Review
- Leveraging Genomic and Bioinformatic Analysis to Enhance Drug Repositioning for Dermatomyositis.Bioengineering (Basel, Switzerland) · 2023Article
- Adverse side effects of Glatiramer acetate and Interferon beta-1a in patients with multiple sclerosis: A systematic review of case reports.Current journal of neurology · 2023Article
- Analysis of human total antibody repertoires in TIF1γ autoantibody positive dermatomyositis.Communications biology · 2021Article
- Plasma-derived DNA containing-extracellular vesicles induce STING-mediated proinflammatory responses in dermatomyositis.Theranostics · 2021Article
- The changing spectrum of drug-induced myopathies.Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology · 2020Review
- Secondary Causes of Myositis.Current treatment options in neurology · 2020Review
- Type I interferons in host defence and inflammatory diseases.Lupus science & medicine · 2019Review
- Induction or aggravation of other immune-mediated disorders by disease-modifying therapy in treatment of multiple sclerosis.Iranian journal of neurology · 2018Review
- Risk factors and disease mechanisms in myositis.Nature reviews. Rheumatology · 2018Review
- Paraneoplastic edematous dermatomyositis: A rare syndrome observed in a case of small cell lung cancer.Clinics and practice · 2017Article
- Cutaneous Adverse Effects of Neurologic Medications.CNS drugs · 2016Review
- Dermatomyositis flare on imiquimod therapy highlights a crucial role of aberrant TLR7 signalling.RMD open · 2016Article
- Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.International journal of molecular sciences · 2015Article
- Innate immune-response mechanisms in dermatomyositis: an update on pathogenesis, diagnosis and treatment.Drugs · 2014Review
- Rapid exacerbation of multiple sclerosis following the initiation of interferon-β: report of nine cases.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2011Article
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundType I interferons (IFNs) are common therapeutics for several diseases, including viral infections and multiple sclerosis (MS). Although numerous studies have implicated type I INFs with the production of autoantibodies and the development of certain autoimmune disorders, interferon beta has not previously been described in association with dermatomyositis, to our knowledge. Previous microarray studies of muscle biopsy specimens from patients with dermatomyositis disclosed a type I IFN-induced gene expression profile. The central role of plasmacytoid dendritic cell precursors, together with increased type I IFN production, suggests a pivotal role for type I IFNs in dermatomyositis. We report a case of dermatomyositis exacerbated or induced by interferon beta therapy for MS and provide evidence that demonstrates enhanced type I IFN signaling in this patient. OBSERVATIONS: We observed new-onset dermatomyositis in a 57-year-old patient treated with interferon beta for MS. His symptoms were exacerbated temporally by interferon beta injections. Immunohistochemical staining of skin biopsy specimens for myxovirus-resistance protein A (a surrogate marker for cutaneous type I IFN signaling) showed increased staining that correlated temporally with interferon beta treatment and subsequent disease activity. In vitro treatment with interferon beta of peripheral blood mononuclear cells isolated from our patient revealed enhanced type I IFN signaling assessed by interferon-induced gene expression profiles.
conclusionsTo our knowledge, this is the first description of dermatomyositis exacerbated or induced by interferon beta treatment. Our results demonstrate enhanced type I IFN signaling following interferon beta treatment in our patient with dermatomyositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.